[go: up one dir, main page]

WO2007057508A3 - Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol - Google Patents

Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol Download PDF

Info

Publication number
WO2007057508A3
WO2007057508A3 PCT/FI2006/000378 FI2006000378W WO2007057508A3 WO 2007057508 A3 WO2007057508 A3 WO 2007057508A3 FI 2006000378 W FI2006000378 W FI 2006000378W WO 2007057508 A3 WO2007057508 A3 WO 2007057508A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor agonist
opioid receptor
treatment
pain
adrenoceptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FI2006/000378
Other languages
French (fr)
Other versions
WO2007057508A2 (en
Inventor
Uemit Kazim Oezdogan
Janne Laehdesmaeki
Mika Scheinin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of WO2007057508A2 publication Critical patent/WO2007057508A2/en
Publication of WO2007057508A3 publication Critical patent/WO2007057508A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to use of an α2-adrenoceptor antagonist for the preparation of a medicament for treating a mammal, including human, to augment the action of a µ-opioid receptor agonist in the treatment of pain, susceptible to treatment with a µ-opioid receptor agonist, and said µ-opioid receptor agonist is a weakly efficacious µ-opioid receptor agonist or a moderately efficacious µ-opioid receptor agonist. This invention also relates to a corresponding method for the treatment or prevention of pain in a mammal, including human. This invention further relates to pharmaceutical preparations. The preparations comprise a weakly efficacious µ-opioid receptor agonist or a moderately efficacious µ-opioid receptor agonist, and a α2-adrenoceptor antagonist.
PCT/FI2006/000378 2005-11-18 2006-11-17 Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol Ceased WO2007057508A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73774005P 2005-11-18 2005-11-18
US60/737,740 2005-11-18

Publications (2)

Publication Number Publication Date
WO2007057508A2 WO2007057508A2 (en) 2007-05-24
WO2007057508A3 true WO2007057508A3 (en) 2008-03-27

Family

ID=37876013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2006/000378 Ceased WO2007057508A2 (en) 2005-11-18 2006-11-17 Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol

Country Status (1)

Country Link
WO (1) WO2007057508A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4201475A1 (en) 2011-01-03 2023-06-28 The Regents of the University of California High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
MX346312B (en) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Ophthalmic treatments.
US9393409B2 (en) 2011-11-11 2016-07-19 Neuroenabling Technologies, Inc. Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function
EP2821072A1 (en) * 2013-07-01 2015-01-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord disorders
JP6475733B2 (en) 2013-09-06 2019-02-27 ザ ユニバーシティー オブ モンタナ Method for reducing neuronal cell death using haloalkylamine
PL3261645T3 (en) 2015-02-27 2021-12-06 Dechra Limited Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
US12357828B2 (en) 2017-12-05 2025-07-15 Ecole Polytechnique Federale De Lausanne (Epfl) System for planning and/or providing neuromodulation
EP3653260A1 (en) 2018-11-13 2020-05-20 GTX medical B.V. Sensor in clothing of limbs or footwear
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
EP3827875B1 (en) 2019-11-27 2023-07-05 ONWARD Medical N.V. Neuromodulation system
CN116115739B (en) * 2022-12-29 2024-01-09 天津市肿瘤医院（天津医科大学肿瘤医院） Motilin and application of receptor agonist thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025383A1 (en) * 2005-08-30 2007-03-08 Queen's University At Kingston Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025383A1 (en) * 2005-08-30 2007-03-08 Queen's University At Kingston Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AGEEL A M ET AL: "YOHIMBINE PROLONGS THE DURATION OF ANTINOCICEPTIVE ACTIVITY OF MORPHINE IN MICE", INDIAN JOURNAL OF PHARMACOLOGY, XX, XX, vol. 16, 1984, pages 112 - 114, XP008078074, ISSN: 0253-7613 *
AMBROSIO E ET AL: "Effect of yohimbine on the development of morphine dependence in the rat: Lack of involvement of cortical beta-androceptor modifications", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 56, no. 3, 1997, pages 487 - 491, XP003009171, ISSN: 0091-3057 *
EL-KADI A O S ET AL: "The influence of chronic treatment with clonidine, yohimbine and idazoxan on morphine withdrawal", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 132, 1997, pages 67 - 73, XP003009173, ISSN: 0033-3158 *
GEAR R W ET AL: "Enhancement of morphine analgesia by the alpha2-adrenergic antagonist yohimbine", NEUROSCIENCE, NEW YORK, NY, US, vol. 66, no. 1, 1995, pages 5 - 8, XP003009169, ISSN: 0306-4522 *
HOMAYOUN H ET AL: "The role of alpha2-adrenoreceptors in the modulatory effects of morphine on seizure susceptibility in mice", EPILEPSIA, LIPPINCOTT, WILLIAMS AND WILKINS, PHILADELPHIA, PA, US, vol. 43, no. 8, 2002, pages 797 - 804, XP003009170, ISSN: 1528-1167 *
OZDOGAN ET AL: "The analgesic efficacy of partial opioid agonists is increased in mice with targeted inactivation of the alpha2A-adrenoceptor gene", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 529, no. 1-3, 4 January 2006 (2006-01-04), pages 105 - 113, XP005229947, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
WO2007057508A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2007005716A3 (en) Methods of treatment and compositions for use thereof
WO2005107726A3 (en) Method for the treatment of back pain
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2005102338A8 (en) Method of treating neuropathic pain using a crth2 receptor antagonist
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
IL197420A (en) Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one, methods for its preparation, a pharmaceutical composition containing it and uses of such form in the preparation of medicaments for treatment of the human body
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MX2010009447A (en) Use of lhrh antagonists at non-castrating doses.
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
PT2210588E (en) Foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
IL207439B (en) Use of an anti-calcitonin gene-related peptide (cgrp) antagonist antibody for the manufacture of a medicament for the prevention and/or treatment of arthritic pain
IL221795B (en) Use of a pharmaceutical composition of methylnaltrexone, or a salt thereof, in the preparation of a medicament for treating the side effects of opioid treatment
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2003070191A3 (en) Tamper-resistant transdermal opioid delivery devices
UA101309C2 (en) Activin-actrii antagonists thereof and uses for increasing red blood cell levels
WO2008128126A8 (en) Compositions and methods for prophylaxis and treatment of addictions
WO2008133928A3 (en) Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
WO2008043107A3 (en) Use of tight junction antagonists to treat inflammatory bowel disease
BRPI0921097A2 (en) pyrazol-3 carboxamide derivative compound with 5-ht2b receptor antagonist activity, preventive or therapeutic agent, pharmaceutical composition and use of the compound or pharmaceutically acceptable salt thereof and method or prevention or treatment.
WO2007057508A3 (en) Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2006086693A3 (en) Medical devices

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06820059

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06820059

Country of ref document: EP

Kind code of ref document: A2